Skip to NavigationSkip to content

FDA rejects Allergan's Abicipar pegol for neovascular age-related macular degeneration over benefit/risk concerns

Published on 29/06/20 at 11:27am

The FDA has moved to reject Allergan’s vascular endothelial growth factor (VEGF) factor A inhibitor, Abicipar pegol, as treatment for the eye condition known as neovascular age-related macular degeneration (nAMD).

The drug application was supported by data from two trials which showed the non-inferiority of Abicipar pegol to Genentech’s Lucentis (ranibizumab) in treatment-naïve (nAMD), with six or eight injections of the former proving as effective as 13 doses of the latter after 52 weeks.

The rate of adverse events was also comparable across three treatment arms presented in the study, but upon reviewing supplied data, the US regulator ruled that the “rate of intraocular inflammation observed following administration of Abicipar pegol 2mg/0.06 mL results in an unfavourable benefit-risk ratio.” Further specifics of the rejection were not given.

AbbVie completed its $63 billion acquisition of Allergan in May this year, and now says it plans to meet with FDA representatives to discuss the regulators decision and the path forward.

“We continue to believe in the need for treatment options that provide patients with reliable vision gains and less frequent dosing for the treatment of nAMD,” explained Michael R Robinson, Vice President, Global Therapeutic Area Head, Ophthalmology at AbbVie. “We are committed to working with the FDA to determine the appropriate next steps for Abicipar pegol.”

Matt Fellows


I am a person who is very much interested in updating my knowledge on various things especially medical-related things. More experiment are done in the medical field which brings out a good result and this post also as something that is related to the medical real estate virtual tour services

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches